论文部分内容阅读
探讨间皮瘤相关抗体-1(HBME-1)、半乳糖凝集素-3(Galectin-3)及粘附分子CD44v6在甲状腺滤泡癌(Follicular ThyroidCarcinoma,FTC)与不典型腺瘤(Atypical Thyroid Adenoma,ATA)中的表达差异,寻找有助于二者临床病理诊断的肿瘤标记物及探索其部分发病机制,拟解决在甲状腺临床病理中对良、恶性难以确定的滤泡性肿瘤的准确判定及对其预后的预示作用。采用免疫组化SP三步法检测37例FTC及18例ATA中HBME-1、Galectin-3和CD44v6的表达,以10例嗜酸性腺瘤(OncocyticThyroid Adenoma,OTA)、8例普通滤泡性腺瘤(Follicular Thyroid Adenoma,FTA)、7例甲状腺乳头状癌(Papillary ThyroidCarcinoma,PTC)及5例尸检正常甲状腺组织作为对照。结果显示,HBME-1、Galectin-3及CD44v6在FTC中的阳性表达率分别为70.3%、64.9%和62.2%,在ATA中阳性表达率分别为66.7%、61.1%和61.1%,三者在FTC与ATA中的表达差异均无统计学意义(χ2分别为0.074、0.094、0.245,P值分别为0.786、0.759、0.620,P值均>0.05);在10例OTA中的表达均为100%;8例FTA中的表达分别为3/8例、6/8例及4/8例;7例PTC的表达分别为7/7例、6/7例及7/7例;5例正常尸检甲状腺组织均无表达。由此得出结论:HBME-1、Galectin-3和CD44v6对FTC与ATA的临床病理鉴别诊断无统计学意义,但提示三者可能在甲状腺滤泡癌与不典型腺瘤的发病机制及进展过程中起着某种共同作用。由于此3种标记物已被证实在诸多肿瘤的发生、发展过程中起着重要作用,故在实际甲状腺临床病理诊断中对表达此3种标记物的良、恶性难以确定的病例可能提示其恶性程度增高,尽管不足以诊断为癌,但仍应加强随访。有关FTC与ATA的临床病理诊断与鉴别诊断及二者的发病机制尚有待于进一步的探索和研究。
To investigate the expression of HBME-1, Galectin-3 and CD44v6 in Follicular Thyroid Carcinoma (FTC) and Atypical Thyroid Adenoma (Atypical Thyroid Adenoma) , ATA) to find the tumor markers that contribute to their clinicopathological diagnosis and to explore some of the pathogenesis, and to solve the accurate determination of follicular tumors difficult to determine in the clinical and pathological thyroid Predict the prognosis of its role. The expression of HBME-1, Galectin-3 and CD44v6 in 37 cases of FTC and 18 cases of ATA was detected by immunohistochemical SP three-step method. Oncocytic Thyroid Adenoma (OTA), 8 cases of common follicular adenoma Follicular Thyroid Adenoma (FTA), Papillary Thyroid Carcinoma (PTC) in 7 cases and Normal thyroid tissue in 5 cases were used as control. The positive rates of HBME-1, Galectin-3 and CD44v6 in FTC were 70.3%, 64.9% and 62.2%, respectively. The positive rates of HBME-1, Galectin-3 and CD44v6 in ATA were 66.7%, 61.1% and 61.1% There was no significant difference between FTC and ATA (χ2 = 0.074,0.094,0.245, P = 0.786,0.759,0.620, P> 0.05). The expression of OTA in 10 cases was 100% ; 8 cases of FTA expression were 3/8 cases, 6/8 cases and 4/8 cases; 7 cases of PTC were 7/7 cases, 6/7 cases and 7/7 cases; 5 cases of normal autopsy Thyroid tissue were not expressed. Conclusions: HBME-1, Galectin-3 and CD44v6 have no statistical significance in the differential diagnosis of FTC and ATA, but they may be related to the pathogenesis and progression of follicular thyroid carcinoma and atypical adenoma Play a certain role in common. Since these three kinds of markers have been proved to play an important role in the occurrence and development of many tumors, the malignant and malignant cases of benign and malignant tumors that express these three markers in the clinicopathological diagnosis of thyroid may be malignant To a high degree, although not enough to diagnose cancer, but should be strengthened follow-up. The clinical pathological diagnosis and differential diagnosis of FTC and ATA and their pathogenesis remains to be further explored and studied.